Statement of deviation or variation for the Quarter ended 30th September, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genpharmasec Ltd has filed a quarterly compliance statement confirming that there is no deviation or variation in the use of proceeds from its Rights Issue, which raised Rs. 4,845.05 lakhs (allotment date: 21st February 2024). The company has fully utilised funds for most stated purposes: Rs. 1,443.58 lakhs to acquire equity shares of Derren Healthcare and make it a subsidiary, Rs. 1,643.86 lakhs for working capital, Rs. 1,138.47 lakhs for general corporate purposes, and Rs. 25 lakhs for issue expenses. However, only Rs. 289 lakhs out of the originally allocated Rs. 588 lakhs has been utilised for repayment/prepayment of borrowings. The Audit Committee and auditors had no comments on the statement.
This is a routine regulatory filing confirming disciplined use of Rights Issue funds with no deviations from stated objectives, which is a positive sign for shareholders. The partial utilisation of borrowing repayment proceeds may indicate the company is taking longer than expected to pay down debt, but overall fund usage is on track.